NASDAQ: LEXXLexaria Bioscience Corp Stock
$3.13-0.17 (-5.15%)
Updated Sep 6, 2024
LEXX Price
$3.13
Fair Value Price
-$1.61
Market Cap
$49.49M
52 Week Low
$0.85
52 Week High
$6.85
P/E
-7.11x
P/B
4.89x
P/S
143.02x
PEG
N/A
Dividend Yield
N/A
Revenue
$376.85k
Earnings
-$4.83M
Gross Margin
98.7%
Operating Margin
-1,280.99%
Profit Margin
-1,288.5%
Debt to Equity
0.03
Operating Cash Flow
-$5M
Beta
0.68
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LEXX Overview
Lexaria Bioscience Corporation is a biotech company developing a drug delivery technology, DehydraTECH, that improves the way active pharmaceutical ingredients enter the bloodstream. Dehydra being evaluated for orally administered anti-viral drugs and non-steroidal anti-inflammatory drugs. Lexaria Bioscience was incorporated in 2004 and is headquartered in Kelowna, British Columbia, Canada.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LEXX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LEXX ($3.13) is overvalued by 293.91% relative to our estimate of its Fair Value price of -$1.61 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LEXX ($3.13) is not significantly undervalued (293.91%) relative to our estimate of its Fair Value price of -$1.61 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LEXX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LEXX due diligence checks available for Premium users.
Be the first to know about important LEXX news, forecast changes, insider trades & much more!
LEXX News
Valuation
LEXX fair value
Fair Value of LEXX stock based on Discounted Cash Flow (DCF)
Price
$3.13
Fair Value
-$1.61
Undervalued by
293.91%
LEXX ($3.13) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LEXX ($3.13) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LEXX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LEXX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.11x
Industry
-46.85x
Market
24.57x
LEXX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.89x
Industry
6.22x
LEXX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LEXX's financial health
Profit margin
Revenue
$84.0k
Net Income
-$1.8M
Profit Margin
-2,121.1%
LEXX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
LEXX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.0M
Liabilities
$271.4k
Debt to equity
0.03
LEXX's short-term assets ($9.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LEXX's short-term assets ($9.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LEXX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LEXX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.3M
Investing
-$22.0k
Financing
$5.0M
LEXX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LEXX vs Biotech Stocks
Lexaria Bioscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.